Everything below concerns obesity research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-09. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
An entrée or main course, typically full meals consisting of preserved and nonperishable precooked meat, vegetables, legumes, grains, rice, or staple foods; dehydrated soup or broth may also be offered, often in the form of bouillon cubes Side dishes or appetizers such as crackers or biscuits, spreads (commonly cheese spread, peanut butter, jam or jelly, chocolate spread, or pâté), pickles, or preservable salad (usually potato salad, tuna salad, or fruit salad) Desserts or snacks such as candy, chocolate, dried fruits, nuts, cookies, cakes, pastries, cereal bars, or energy bars Drink mixes, commonly juice, powdered milk, instant coffee, instant tea, hot chocolate, energy drinks, protein drinks, or soft drinks Food supplements such as condiments, chewing gum, dietary supplements, and water purification tablets Tableware, typically mess kits and eating utensils (usually a single multipurpose utensil like a spoon, spork, chopsticks, or lusikkahaarukka) Additional items provided for personnel to use for themselves, such as multipurpose paper, napkins or tissue paper, toilet paper, matches, cigarettes (historically), and solid fuel Field rations may come in different varieties, or carry multiple meals, for breakfast, lunch, dinner, or supper. Vegetarian, vegan, and religious diet variants may be available if a military's demographics necessitate them.
=== Analogues === Analogues of 4-HO-MET include psilocin (4-HO-DMT), 4-HO-DET (ethocin), 4-HO-MiPT (miprocin), 4-HO-DPT (deprocin), 4-HO-MPT (meprocin), 4-HO-DALT (dalocin), and 4-HO-MALT (malocin), among others. 4-AcO-MET (metacetin) and 4-PrO-MET are ester prodrugs of 4-HO-MET. Other analogues of 4-HO-MET include methylethyltryptamine (MET), 5-HO-MET, and 5-MeO-MET.
=== Production area === India is the largest producer of moringa, with an annual production of 1.2 million tonnes of fruit from an area of 380 km2 (150 sq mi). Among Indian states, Tamil Nadu leads in cultivation area followed by Andhra Pradesh and Karnataka. Moringa is grown in home gardens and as living fences in South and Southeast Asia, where it is commonly sold in local markets. In the Philippines and Indonesia, it is commonly grown for its leaves, which are used as food. Moringa is also actively cultivated by the World Vegetable Center in Taiwan, a center for vegetable research. More generally, moringa grows in the wild or is cultivated in Central America and the Caribbean, northern countries of South America, Africa, South and Southeast Asia, and various countries of Oceania. As of 2010, cultivation in Hawaii was in the early stages for commercial distribution in the US.
Sources: en.wikipedia.org
Carrey was criticized for being "ignorant when it comes to vaccines" by Arthur Caplan, head of the Division of Medical Ethics at New York University, and by Jeffrey Kluger, senior writer at Time, who described his anti-vaccination statements as "angry, dense and immune to reason".
In the late 20th and early 21st centuries, fishing off the European and American coasts severely depleted stocks and become a major political issue. The necessity of restricting catches to allow stocks to recover upset the fishing industry and politicians who are reluctant to hurt employment.
Lee Limbird (born November 27, 1948, in Philadelphia, Pennsylvania) is a pharmacologist, Dean of the School of Natural Science, Mathematics and Business & Professor in the Department of Life and Physical Sciences at Fisk University, Nashville, Tennessee. Limbird has been recognized for "outstanding scientific contributions in research and mentoring in pharmacology", in particular her "pioneering research on alpha-2 adrenergic receptors and how they relate to the regulation of blood pressure, sedation, pain suppression and opioid drug action". Among other awards, she received the Julius Axelrod Award from the American Society for Pharmacology and Experimental Therapeutics (ASPET) in 2013.
Sources: en.wikipedia.org
==== Post reform organisations ==== The 1st Hydropower Corps was converted into the China Anneng Construction Group's 1st Engineering Bureau (Headquartered in Nanning) on 19 November 2019. The 2nd Hydropower Corps was converted into the China Anneng Construction Group's 2nd Engineering Bureau (Headquartered in Nanchang) on 14 November 2019. The 3rd Hydropower Corps was converted into the China Anneng Construction Group's 3rd Engineering Bureau (Headquartered in Chengdu) on 12 November 2019. It has branches in Wuhan and Chongqing.
== Society and culture == PRP has received attention in media as a result of its use by athletes. In the 2010s, cosmetic procedures marketed under the name of "vampire facials" grew in popularity, fueled by celebrity endorsement. These facials generally center on PRP treatment, and usually involve microneedling. In April 2024, the CDC announced that three women who had been patients at the Albuquerque, New Mexico, VIP Spa had been diagnosed with HIV after getting such facials; another almost 200 former clients and their sexual partners tested negative. Investigations by New Mexico and federal health officials revealed that the woman performing the procedures was operating out of an unlicensed medical spa, practicing without a medical license, and reusing blood-contaminated equipment intended for single-patient use without sterilization between patients. PRP has been injected into the vagina, in a procedure called "O-shot" or "orgasm shot", with claims to improve orgasms. No evidence supports such claims.
=== Organizations === The World Health Organization Department of Food Safety and Zoonoses (FOS) provides scientific advice for organizations and the public on issues concerning the safety of food. Its mission is to lower the burden of foodborne disease, thereby strengthening the health security and sustainable development of Member States. Foodborne and waterborne diarrhoeal diseases kill an estimated 2.2 million people annually, most of whom are children. WHO works closely with the Food and Agriculture Organization of the United Nations (FAO) to address food safety issues along the entire food production chain—from production to consumption—using new methods of risk analysis. These methods provide efficient, science-based tools to improve food safety, thereby benefiting both public health and economic development.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.